MagForce AG Publishes First Quarterly Shareholder Letter

MagForce AG Publishes First Quarterly Shareholder Letter 
BERLIN -- (Marketwired) -- 07/24/13 --  MagForce AG  / 
MagForce AG Publishes First Quarterly Shareholder Letter. 
Ad hoc announcement according to Section  15 WpHG. Processed and
transmitted by Thomson Reuters ONE. 
The issuer is solely responsible for the content of this
MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company
in the area of nanotechnology with a focus on oncology,
today its first "Shareholder Letter". 
Subsequently, such shareholder letters shall be published quarterly
in order to keep shareholders well informed about the ongoing
developments and progress. 
The shareholder letter can be downloaded here: 
Key points are 
* Personal introduction of Dr. Ben Lipps, designated CEO and
Chairman of the 
Management Board 
* Focus on recurrent Glioblastoma Multiform Cancer (GBM) and
Prostate Cancer 
* Details to GBM post-marketing study 
* Search for strategic partners in Emerging Markets. 
About MagForce AG 
MagForce  AG is a leading medical device company in the field of
nanomedicine in oncology,  listed  in  the  entry  standard  (MF6). 
The  Company's proprietary,
NanoTherm((R)) therapy, enables the
targeted treatment of solid tumors through the intratumoral  
generation   of   heat   via   activation   of
nanoparticles.  NanoTherm((R)), NanoPlan((R)), and 
NanoActivator(TM) are components of  the therapy and have received
EU-wide regulatory approval as medical devices
for  the  treatment 
of  brain  tumors. MagForce, NanoTherm((R)), NanoPlan((R)), and
NanoActivator(TM)  are trademarks of MagForce AG in selected
countries. For more
information, please visit 
Full Resume Dr. Ben Lipps 
Dr.  Ben J. Lipps became Chairman and  Chief Executive Officer of the
Board of Fresenius Medical Care in May 1999. In December
2012 he stepped down as Chairman  of the  Management Board  and CEO. 
During his term, Fresenius Medical
Care's sales tripled from 3.8 to
12.8 billion dollars, and the annual net profit
grew 6 times to 1.1
billion dollars. 
He  was also  Chief Executive  Officer of  Fresenius Medical  Care
North America
until  February 2004. He was President, Chief Executive
Officer, Chief Operating
Officer  and  a  director  of  Fresenius 
USA from October 1989 through February
2004, and  served in  various
capacities  with Fresenius  USA's predecessor from
1985 through 1989. 
He  earned his master's  and doctoral degrees  at the Massachusetts
Institute of Technology in chemical engineering. Before joining the
Fresenius Group in 1985,
Dr. Lipps held several research management
positions in various companies, among
them with DOW Chemical. 
This release may contain forward-looking statements and information
which may be identified by formulations using terms such as "expects",
"aims", "anticipates",
"intends",  "plans", "believes",  "seeks",
"estimates"  or "will". Such forward-looking   statements   are  
based  on  our  current  expectations and  certain assumptions, 
which may be subject to a  variety of risks and uncertainties. The
results  actually achieved  by MagForce  AG may  substantially differ
from these
forward-looking  statements. MagForce AG  assumes no
obligation  to update these
forward-looking  statements or  to
correct  them in  case of developments, which
differ from those,
MagForce_Press Release_July 24, 2013: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: MagForce AG  via Thomson Reuters ONE 
Anne Hennecke
MC Services AG 
T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759 
Press spacebar to pause and continue. Press esc to stop.